Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer

Chinese Journal of Oncology

Volumn 33, Issue 4, 2011, Pages 295-298

  Zhao, Wen Ying ^a   Chen, Dong Yun ^a   Qi, Quan ^a  

^a WANNAN MEDICAL COLLEGE   (China)

Author keywords

Capecitabine; Chemotherapy; Irinotecan; Oxaliplatin; Stomach neoplasms

Indexed keywords

CAPECITABINE; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CONTROLLED STUDY; DIARRHEA; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; STOMACH CANCER; THERAPY EFFECT; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEURITIS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; REMISSION INDUCTION; STOMACH NEOPLASMS; YOUNG ADULT;

EID: 80053551986     PISSN: 02533766     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0253-3766.2011.04.013     Document Type: Article

References (18)

1. Park YH, Kim BS, Ryoo BY, et al. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer, 2006, 94:959-963.
2. Baek JH, Kim JG, Jeon SB, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer, 2006, 94:1407-1411. (Pubitemid 43772274)
3. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 2000, 92:205-216.
4. Terashima M, Fujiwara H, Takagane A, et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer, 2002, 38:2375-2381. (Pubitemid 35387489)
5. Okines A, Chau I, Cunningham D. Capecitabine in advanced gastric cancer. Expert Opin Pharmacother, 2007, 8:2851-2861. (Pubitemid 350199215)
6. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol, 2009, 20:666-673.
7. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol, 2004, 22:2084-2091. (Pubitemid 41095141)
8. Twelves C, Boyer M, Findlay M, et al. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer, 2001, 37:597-604. (Pubitemid 32261017)
9. Sena K, Morotome Y, Baba O, et al. Gene expression of growth differentiation factors in the developing periodontium of rat molars. J Dent Res, 2003, 82:166-171. (Pubitemid 41766037)
10. Beretta E, Di Bartolomeo M, Buzzoni R, et al. Irinotecan, fluorouracil and folinic acid (FOLFIRI) as effective treatment combination for patients with advanced gastric cancer in poor clinical condition. Tumori, 2006, 92:379-383. (Pubitemid 44867398)
11. Kanat O, Evrensel T, Manavoglu O, et al. Single-agent irinotecan as second-line treatment for advanced gastric cancer. Tumori, 2003, 89:405-407. (Pubitemid 37279923)
12. Chun JH, Kim HK, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol, 2004, 34:8-13. (Pubitemid 43118052)
13. Oh SC, Sur HY, Sung HJ, et al. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. Br J Cancer, 2007, 96:1514-1519. (Pubitemid 46762953)